1. Report Overview
1.1 A Brief Overview of the Pharmaceutical Industry
1.2 An Introduction to the Rise of Generic Drugs
1.2.1 Structure of the Generics Industry
1.2.2 Segmentation of Global Generic Drugs Market
1.3 Market Definition and Scope of this Report
1.3.1 Generic Drugs:
1.3.2 Oral Route of Administration:
1.3.3 Dermal/Topical Route of Administration:
1.3.4 Inhalants Route of Administration:
1.3.5 Injectable Route of Administration:
1.3.6 Hospital Pharmacy
1.3.7 Retail Pharmacy
1.3.8 Oncology
1.3.9 Diabetes
1.3.10 Auto-immune Diseases
1.4 Global Generic Drugs: Market Overview
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is this Report for?
1.9 Methodology
1.9.1 V-Shaped Recovery
1.9.2 U-Shaped Recovery
1.9.3 W-Shaped Recovery
1.9.4 L-Shaped Recovery
1.10 Frequently Asked Questions (FAQs)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. Executive Summary
2.1 Introduction
2.2 Impact of Corona virus on the Global Economy
3. Generic Drugs Industry Overview
3.1 Introduction & Evolution of Generic Drugs
3.1.1 What are Generic Drugs?
3.2 Types of Generics - Authorized, Branded and Unbranded
3.2.1 Complex Generics
3.2.2 Simple Generics
3.2.3 Adequate Market Size
3.2.4 Patent-expired Therapies
3.5.5 Older Products Still Used
3.2.6 Long-term Use
3.2.7 Straightforward Production Technology
3.2.8 Drugs Used in Primary Care
3.2.9 Super generics
3.2.10 Biosimilars
3.3 Classification of Generic Drug Market
3.4 Is Generic Substitution Bad News for Pharma Business?
3.5 The 'Ever-greening' of Pharmaceutical Products
4. Regulatory Environment: Major Generic Issues
4.1 United States
4.1.1 Evolving Situation in the U.S.
4.1.2 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.
4.1.3 Quality Considerations in Demonstrating Biosimilarity to a Reference Product.
4.1.4 User Fees
4.2 European Union
4.2.1 EU Marketing Authorization Systems
4.2.2 The Centralized Procedure
4.2.3 Decentralized and Mutual Recognition Procedures
4.2.4 Mutual Recognition Procedure
4.2.5 Applications under Article 10 (Generic Products)
4.2.6 EU Provisions
4.3 Japan
4.3.1 Approval of Pharmaceuticals
4.3.2 Regulation of Biosimilars
4.4 Hatch-Waxman and Bolar
4.5 Defensive Strategies by 'Big Pharma'
4.6 'AUTHORIZED GENERICS'
4.7 User Fees
4.8 Changing Climate for Generics
4.9 Situation in Europe
4.10 Patents and IP
4.11 Supplementary Protection Certificates
5. Market Dynamics
5.1 Global Market Overview
5.2 The Rise of the Global Generic Drugs Market in 2019
5.3 Drivers and Restraints for the Global Generic Drugs Market 2020-2030
5.3.1 Drivers
5.3.2 Restrains
5.4 Market Trends
5.5 National Markets that Will Drive Generic Drugs Growth
5.6 Changes in Market Shares by National Market 2020-2030
5.7 Increasing Acceptance of Generics amongst Consumers
5.8 Affordable Care Act: Expanding Medicare Coverage
5.9 Impact of COVID-19 on Pharma Supply Chains
5.10 Disruption of Clinical Trials
6. Global Generic Drugs Market Analysis
6.1 Global Generic Drugs Market in Terms of Value
6.2 Global Generic Drugs Market by Drug Delivery
6.2.1 Market Share Analysis by Drug Delivery
6.3 Global Generic Drugs Market by Application
6.3.1 Market Share Analysis
6.4 Global Generic Drugs Market by Distribution Channel
6.4.1 Market Share Analysis
7. Generic Drugs Market Analysis by Geography
7.1 V-Shaped Recovery of Global Generic Market by Region
7.2 W-Shaped Recovery of Global Generic Market by Region
7.3 U-Shaped Recovery of Global Generic Market by Region
7.4 L-Shaped Recovery of Global Generic Market by Region
8. North America Generic Drugs Market Analysis
8.1 Generic Drugs in the North America: Market Overview
8.2 The Hatch-Waxman Act and Its Ongoing Effects
8.3 Consolidation in the Drug Development and Supply Chain Driving North America Generics
8.4 North America Generic Drug Market: Drivers and Restraints 2020-2030
8.4.1 Drivers:
8.4.2 Restraints:
8.5 Leading Companies Operating within the North America Generic Drugs Market
8.6 Increasing Acceptance of Generics amongst Consumers
8.7 Affordable Care Act: Expanding Medicare Coverage
8.8 North America Generic Drugs Market - Strategy Analysis
8.8.1 Will Biosimilars Dictate the Future of the US Generic Market?
8.8.2 The Backlog of ANDA Application
8.9 The Generic Drug User Fee Amendments (GDUFA)
8.10 Shortages of Generic Drugs Will Restrain the Market
8.11 The Anti-Competitive 'Pay for Delay' Act
8.17 North America Generic Drugs Market by Drug Delivery
8.18 North America Generic Drugs Market by Application
8.19 North America Generic Drugs Market by Distribution Channel
8.12 North America Generic Drugs Market by Country
8.13 U.S Generic Drug Market: A Range of Factors Contributing To Growth
8.14 Canada Generic Drugs Market: A Range of Factors Contributing to Growth
8.15 United States
8.15.1 Health and Healthcare
8.15.2 Generics Market
8.15.4 Generic Prices
8.15.5 'Carve-outs'
8.15.6 Generics Industry
8.15.7 Regulation in the United States
8.15.8The Future
8.16 Canada
8.16.1 Pharmaceutical Market
8.16.2 Generics Market
8.16.3 How Generics Are Supplied
9. Europe Generic Drugs Market Analysis
9.1 Generic Drugs in Europe: Market Overview
9.2 Why Growth in Some Markets is being hindered?
9.3 Predominant Pricing Systems and Generic Penetration in European Markets
9.4 Lower Patient Co-Payments Drive Demand for Generics
9.5 The Effects of Tendering for Generic Medicines
9.6 Will Europe Move towards Free-Pricing Systems?
9.7 Challenges in the European Regulatory Environment
9.7.1 Ending Anti-Competitive 'Pay for Delay' Tactics in Europe
9.7.2 FDA and EMA Joint Data Sharing and Inspections
9.8 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
9.9 United Kingdom Generic Drugs Market: A Mature Market with Growth Potentials
9.9.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
9.10 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
9.11 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
9.11.1 The Tightening of Italy's Patent Legislations
9.11.2 The Italian Healthcare System - A Tale of Falling Budgets
9.12 Spain Generic Drugs Market: Room for Growth
9.13 Cost-Containment Measures Helping to Boost Generic Drug Use
9.14 Regulations in Europe
9.14.1 EU Marketing Approval Procedures
9.14.2 The 8+2+1 Rule: EU Data Exclusivity
9.14.3 Supplementary Protection Certificates
9.14.4 Variations in Drug Development Regulation between European Countries
9.14.5 The Move towards Harmonization of Standards
9.14.6 The Impact of Europe Unitary Patent System on Generic Drug
9.14.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
9.15 Europe Generic Drugs Market by Drug Delivery
9.16 Europe Generic Drugs Market by Application
9.17 Europe Generic Drugs Market by Distribution Channel
9.18 Europe Generic Drugs Market by Country
9.19 France
9.16.1 Health and Healthcare
9.16.2 Healthcare Provision
9.19.3 Pharmaceutical Market
9.19.4 France Generics Market Sales Estimation and Forecast
9.20 Germany
9.20.1 Health and Healthcare
9.20.2 Provision of Healthcare
9.20.3 Pharmaceutical Market
9.20.4 Price Controls
9.20.5 Germany Generics Market Sales Estimation and Forecast
9.18 Italy
9.18.1 Health and Healthcare
9.18.2 Healthcare System
9.18.3 Pharmaceutical Market
9.18.4 Pharmaceutical Industry
9.18.5 Generics Market
9.19 Spain
9.19.1 Health and Healthcare
9.19.2 Healthcare Provision
9.19.3 Pharmaceutical Services
9.19.5 Generics Market
9.19.6 Generics Industry
9.20 United Kingdom
9.20.1 Health and Healthcare
9.20.2 Healthcare Provision
9.20.3 Private Sector Involvement
9.20.4 Pharmaceuticals
9.20.5 Pharmaceutical Market
9.20.6 U.K Generics Market
9.21 Rest of Europe
10. Asia-Pacific Generic Drugs Market Analysis
10.1 Generic Drugs in Asia-Pacific: Market Overview
10.2 Asia-Pacific Generic Drugs Market by Drug Delivery
10.3 Asia-Pacific Generic Drugs Market by Application
10.4 Asia-Pacific Generic Drugs Market by Distribution Channel
10.5 Asia-Pacific Generic Drugs Market by Country
10.3 India Generic Market
10.3.1 Pharma Industry
10.3.2 Patent Reform
10.3.3 Generics Industry
10.3.4 Indian Generic Drugs Market: Sales Forecast 2020-2030
10.3.5 The Reforms to India's Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
10.3.6 Expansion of the National Healthcare Coverage Increases the Need for Generics
10.3.7 Has Recent Manufacturing Quality Failures Dented India's Generics Growth?
10.4 Chinese Generic Drugs Market
10.4.1 China Market Overview
10.4.2 The Major Drivers of Growth in the Chinese Generics Market
10.4.3 Pharmaceutical Market
10.4.4 Domestic Industry
10.4.5 Foreign Company Involvement
10.4.6 Importance of R&D
10.4.7 Challenges
10.4.8 Market Trends
10.4.9 Regulatory Changes
10.4.10 Generics Exports
10.4.11 Domestic Generics Market
10.4.12 Local Dominance
10.4.13 Regulations in China
10.4.15 Chinese Generic Drugs Market: Sales Forecast 2020-2030
10.4.3 Compulsory Licensing of Generic Drugs
10.4.4 Expansion of Healthcare Coverage and Reimbursement
10.4.5 The Impacts of Price Controls and the Anhui Model
10.5 South Korean Generic Drugs Market
10.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
10.5.2 KORUS FTA: The Free Trade Agreement between South Korea and the US
10.5.3 The Free Trade Agreement between Korea and the European Union
10.6 Japanese Generic Drugs Market
10.6.1 Public Perception of Generics in Japan
10.6.2 Health and Healthcare
10.6.3 Generics Market
10.6.4 Generics Industry
10.6.5 Regulations in Japan
10.6.6 Government Initiatives Driving Generic Penetration
10.6.7 Japanese Attitudes to Generic Drugs
10.6.8 Japanese Generic Drugs Market: Sales Forecast 2020-2030
10.7 Australia Generic Drugs Market
10.7.1 Australia Generic Drugs Market: Sales Forecast 2020-2030
10.8 Rest of Asia-Pacific Generic Drugs Market
11. Middle East and Africa Generic Drugs Market
11.1 Generic Drugs in the Middle East & Africa Market: Market Overview
Rest of Middle East and Africa Generic Drugs Market
11.2 Middle East & Africa Generic Drugs Market by Drug Delivery
11.10 Middle East & Africa Generic Drugs Market by Application
11.11 Middle East & Africa Generic Drugs Market by Distribution Channel
11.2 Middle East & Africa Generic Drugs Market by Country
11.3South Africa Generic Drugs Market
11.4Turkey Generic Drugs Market
11.5 Algeria Generic Drugs Market
11.6 Angola Generic Drugs Market
11.7 Egypt Generic Drugs Market
12. Latin America Generic Drugs Market
12.1 Generic Drugs in the Latin American Market: Market Overview
12.7 Latin America Generic Drugs Market by Drug Delivery
12.8 Latin America Generic Drugs Market by Application
12.9 Latin America Generic Drugs Market by Distribution Channel
12.2 Latin America Generic Drugs Market by Country
12.3 Brazil Generic Drugs Market
12.3.1 Pharmaceutical Market
12.3.2 Generics Market
12.3.3 Future Prospects
12.3.4 ProGenericos
12.4 Argentina Generic Drugs Market
12.5 Mexico Generic Drugs Market
12.6 Rest of Latin America Generic Drugs Market
13. Porter's Five Forces Analysis of Global Generic Drugs Market
13.1 Overview
13.2 Threat of New Entrants - Low
13.3 Bargaining Power of Suppliers - Low
13.4 Bargaining Power of Buyers - Medium
13.5 Threat of Substitutes - Medium / Low
13.6 Competitive Rivalry - High
14. Leading Generic Drugs Manufacturing Company Profiles
14.1 Taisho Pharmaceutical Holdings Co Ltd
14.1.1 Company Details
14.1.2 Company Overview
14.1.3 Company Financial Analysis
14.3 Nippon Chemiphar Co., Ltd.
14.3.1 Company Details
14.3.2 Company Overview
14.3.3 Company Financial Analysis
14.4 H. Lundbeck A/S
14.4.1 Company Details
14.4.2 Company Overview
14.4.3 Company Financial Analysis
14.5 ASKA Pharmaceutical Co., Ltd.
14.5.1 Company Details
14.5.2 Company Overview
14.5.3 Company Financial Analysis
14.6 Teva Pharmaceuticals
14.6.1 Company Details
14.6.2 Company Overview
14.6.3 Company Financial Analysis
14.7 Novartis AG
14.7.1 Company Details
14.7.2 Company Overview
14.7.3 Company Financial Analysis
14.8 Pfizer Inc.
14.8.1 Company Details
14.8.2 Company Overview
14.8.3 Company Financial Analysis
14.9 Mylan NV
14.9.2 Company Overview
14.9.3 Company Financial Analysis
14.10 Abbott Laboratories
14.10.1 Company Details
14.10.2 Company Overview
14.10.3 Company Financial Analysis
14.11 Fresenius SE & Co KGaA
14.11.1 Company Details
14.11.2 Company Overview
14.11.3 Company Financial Analysis
14.12 Sun Pharmaceutical Industries Ltd
14.12.1 Company Details
14.12.2 Company Overview
14.12.3 Company Financial Analysis
14.13 Sanofi SA
14.13.1 Company Details
14.13.2 Company Overview
14.13.3 Company Financial Analysis
14.14 Roche Holding
14.14.1 Company Details
14.14.2 Company Overview
14.14.3 Company Financial Analysis
14.15 Lupin Pharmaceuticals
14.15.1 Company Details
14.15.2 Company Overview
14.15.3 Company Financial Analysis
15. Global Generic Drugs Mapping and Analysis
15.1 Mapping of Drug Patents Expiring in Coming Years
15.1.1 Atrovent HFA (ipratropium hfa)
15.1.2 Bydureon (exenatide)
15.1.3 Chantix (varenicline)
15.1.4 Dexilant (dexlansoprazole)
15.1.5 Inlyta (axitinib)
15.1.6 Namenda (memantine)
15.1.7 Safyral (drospirenone, ethinyl estradiol, levomefolate)
15.1.8 Saphris (asenapine)
15.1.9 Silenor (doxepin)
15.1.10 Sprycel (dasatinib)
15.1.11 Tykerb (lapatinib)
15.1.12 Vigamox (moxifloxacin)
15.1.13 Simulect (basiliximab)
15.1.14 Cosentyx (secukinumab)
15.1.15 Lucentis (ranibizumab)
15.1.16 Vectibix (panitumumab)
15.1.17 Kineret (anakinra)
15.1.18 Mircera (methoxy polyethylete glycol, epoetin alfa)
15.3 Mapping of First Time Drug Approvals
16. Conclusion and Future Implication
Glossary
Associated Reports
Visiongain Report Sales Order Form
AboutVisiongain
VisiongainReportEvaluationForm
List of Tables
Table 1.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 1.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 1.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 1.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 2.1 Global Generic Drugs Market Highlights
Table 2.2 Interim Economic Outlook Forecasts, as on 2 March 2020
Table 4.1 Requirements for NDA and ANDA Applications
Table 5.1 Disruptions of Clinical Trials Due to COVID-19, by Therapeutic Area (Number)
Table 6.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.5 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.6 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.7 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %,CAGR%) (U-Shaped Recovery)
Table 6.8 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.9 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.10 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.11 Global Generic Drugs Market by Application Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.12 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 6.13 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 6.14 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 6.15 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 6.16 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 7.1 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 7.2 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 7.3 Global Generic Drugs Market By Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 7.4 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.1 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.2 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.3 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.4 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.5 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.6 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.7 US Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.8 US Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.9 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.10 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.11 Canada Generic Drugs Market by Country Forecast 2020-2030
Table 8.12 Canada Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.13 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.14 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.15 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.16 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.17 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.18 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.19 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 8.20 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 8.21 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.22 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.23 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 8.24 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 8.25 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.1 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.2 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.3 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.4 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.5 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.6 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.7 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.8 France Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.9 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.10 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.11 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.12 Germany Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.13 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.14 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.15 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.16 Italy Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.17 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.18 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.19 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.20 Spain Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.21 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.22 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.23 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.24 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.25 UK Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.26 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.27 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.28 Rest of Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.29 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.30 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.31 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.32 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.33 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.34 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.35 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.36 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 9.37 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 9.38 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 9.39 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 9.40 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.1 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.2 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.3 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.4 India Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.5 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.6 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.7 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.8 China Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.9 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.10 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.11 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.12 South Korea Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.13 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.14 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.15 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.16 Japan Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.17 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.18 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.19 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.20 Australia Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.21 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.22 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.23 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.24 Rest of APAC Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.25 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.26 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.27 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.28 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.29 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.30 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.31 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.32 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 10.33 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 10.34 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 10.35 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 10.36 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.1 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.2 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.3 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.4 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.5 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.6 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.7 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.8 South Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.9 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.10 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.11 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.12 Turkey Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.13 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.14 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.15 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.16 Algeria Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.17 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.18 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.19 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.20 Angola Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.21 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.22 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.23 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.24 Egypt Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.25 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.26 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.27 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.28 Rest of MEA Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.29 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.30 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.31 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.32 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.33 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.34 East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.35 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.36 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 11.37 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 11.38 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 11.39 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 11.40 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.1 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.2 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.3 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.4 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.5 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.6 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.7 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.8 Brazil Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.9 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.10 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.11 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.12 Argentina Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.13 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.14 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.15 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.16 Mexico Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.17 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.18 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.19 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.20 Rest of LATAM Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.21 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.22 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.23 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.24 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.25 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.26 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table12.27 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.28 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 12.29 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (V-Shaped Recovery)
Table 12.30 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (W-Shaped Recovery)
Table 12.31 Latin America Generic Drugs Market by Distribution Forecast 2020-2030 (US$billion, AGR %, CAGR %) (U-Shaped Recovery)
Table 12.32 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %, CAGR %) (L-Shaped Recovery)
Table 14.1 Taisho Pharmaceutical Holdings Co Ltd (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.2 Taisho Pharmaceutical Holdings Co Ltd Company Revenue 2016-2020 (US$Mn, AGR %)
Table 14.3 Taisho Pharmaceutical Holdings Co Ltd Company Financial Ratios 2019 (USD)
Table 14.4 Taisho Pharmaceutical Holdings Co Ltd Company Growth Parameters 2019 (%)
Table 14.5 Nippon Chemiphar Co., Ltd. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.6 Nippon Chemiphar Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.7 Nippon Chemiphar Co., Ltd. Company Financial Ratios 2019 (USD)
Table 14.8 Nippon Chemiphar Co., Ltd. Company Growth Parameters 2019 (%)
Table 14.9 H. Lundbeck A/S (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.14 H. Lundbeck A/S Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.10 H. Lundbeck A/S Company Financial Ratios 2019 (USD)
Table 14.11 H. Lundbeck A/S Company Growth Parameters 2019 (%)
Table 14.12 ASKA Pharmaceutical Co., Ltd. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.13 ASKA Pharmaceutical Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.14 ASKA Pharmaceutical Co., Ltd. Company Financial Ratios 2019 (USD)
Table 14.15 ASKA Pharmaceutical Co., Ltd. Company Growth Parameters 2019 (%)
Table 14.16 Teva Pharmaceuticals (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.17 Teva Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.18 Teva Pharmaceuticals Company Financial Ratios 2019 (USD)
Table 14.19 Teva Pharmaceuticals Company Growth Parameters 2019 (%)
Table 14.20 Novartis AG (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.21 Novartis AG Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.22 Novartis AG Company Financial Ratios 2019 (USD)
Table 14.23 Novartis AG Company Growth Parameters 2019 (%)
Table 14.24 Pfizer Inc. (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.25 Pfizer Inc. Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.26 Pfizer Inc. Company Financial Ratios 2019 (USD)
Table 14.27 Pfizer Inc. Company Growth Parameters 2019 (%)
Table 14.28 Mylan NV (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.29 Mylan NV Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.30 Mylan NV Company Financial Ratios 2019 (USD)
Table 14.31 Mylan NV Company Growth Parameters 2019 (%)
Table 14.32 Abbott Laboratories (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.33 Abbott Laboratories Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.34 Abbott Laboratories Company Financial Ratios 2019 (USD)
Table 14.35 Abbott Laboratories Company Growth Parameters 2019 (%)
Table 14.36 Fresenius SE & Co KGaA (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.37 Fresenius SE & Co KGaA Company Revenue 2015-2019 (US$Mn, AGR%)
Table 14.38 Fresenius SE & Co KGaA Company Financial Ratios 2019 (USD)
Table 14.39 Fresenius SE & Co KGaA Company Growth Parameters 2019 (%)
Table 14.40 Sun Pharmaceutical Industries Ltd (Executive Leadership, Company Type, Total Company Revenue US$Mn, Headquarters, Founded, , Website)
Table 14.41 Sun Pharmaceutical Industries Ltd Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.42 Sun Pharmaceutical Industries Ltd Company Financial Ratios 2019 (USD)
Table 14.43 Sun Pharmaceutical Industries Ltd Company Growth Parameters 2019 (%)
Table 14.44 Sanofi SA (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.45 Sanofi SA Company Revenue 2015-2019 (US$Mn, AGR %)
Table 14.46 Sanofi SA Company Financial Ratios 2019 (USD)
Table 14.47 Sanofi SA Company Growth Parameters 2019 (%)
Table 14.48 Roche Holding (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.49 Roche Holding Company Revenue 2015-2019 (US $Mn, AGR %)
Table 14.50 Roche Holding Company Financial Ratios 2019 (USD)
Table 14.51 Roche Holding Company Growth Parameters 2019 (%)
Table 14.52 Lupin Pharmaceuticals (Executive Leadership, Company Type, Total Company Revenue US $ Mn, Headquarters, Founded, , Website)
Table 14.53 Lupin Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR%)
Table 14.54 Lupin Pharmaceuticals Company Financial Ratios 2019 (USD)
Table 14.55 Lupin Pharmaceuticals Company Growth Parameters 2019 (%)
Table 15.1: Mapping and Analysis of First Time Drug Approvals
List of Figures
Figure 1.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 1.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 1.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 1.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 3.1 Generic Drugs Classification based on FDA Guidelines
Figure 6.1 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.2 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.3 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.4 Global Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.5 Global Generic Drugs Market Share by Drug Delivery Forecast 2020, 2025, 2030 (%)
Figure 6.6 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.7 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.8 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.9 Global Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.10 Global Generic Drugs Market Share by Application Forecast 2020, 2025, 2030 (%)
Figure 6.11 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.12 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.13 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.14 Global Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 6.15 Global Generic Drugs Market Share by Distribution Channel Forecast 2020, 2025, 2030 (%)
Figure 6.16 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 6.17 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 6.18 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 6.19 Global Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 7.1 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 7.2 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 7.3 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 7.4 Global Generic Drugs Market by Region Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.1 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.2 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.3 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.4 North America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.5 North America Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 8.6 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.7 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.8 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.9 North America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.10 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.11 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.12 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.13 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.14 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.15 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.16 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.17 North America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 8.18 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 8.19 North America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.20 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 8.21 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 8.22 North America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.1 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.2 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.3 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.4 Europe Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.5 Europe Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 9.6 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.7 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.8 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.9 Europe Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.10 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.11 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.12 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.13 Europe Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.14 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.15 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.16 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.17 Europe Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 9.18 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 9.19 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 9.20 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 9.21 Europe Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.1 Asia-Pacific Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 10.2 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.3 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.4 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.5 Asia-Pacific Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.6 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.7 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.8 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.9 Asia-Pacific Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.10 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.11 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.12 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.13 Asia-Pacific Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 10.14 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 10.15 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 10.16 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 10.17 Asia-Pacific Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.1 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.2 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.3 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure11.4 Middle East & Africa Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.5 Middle East & Africa Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 11.6 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.7 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.8 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.9 Middle East & Africa Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.10 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.11 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.12 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.13 Middle East & Africa Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.14 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.15 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.16 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.17 Middle East & Africa Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 11.18 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 11.19 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 11.20 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 11.21 Middle East & Africa Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.1 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.2 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.3 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.4 Latin America Generic Drugs Market by Value Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.5 Latin America Generic Drugs Market Share by Country Forecast 2020, 2025, 2030 (%)
Figure 12.6 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.7 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.8 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.9 Latin America Generic Drugs Market by Country Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.10 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.11 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.12 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.13 Latin America Generic Drugs Market by Drug Delivery Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.14 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.15 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.16 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.17 Latin America Generic Drugs Market by Application Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 12.18 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (V-Shaped Recovery)
Figure 12.19 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (W-Shaped Recovery)
Figure 12.20 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (U-Shaped Recovery)
Figure 12.21 Latin America Generic Drugs Market by Distribution Channel Forecast 2020-2030 (US$billion, AGR %) (L-Shaped Recovery)
Figure 13.1 Porter Five Forces Analysis of Global Generic Drugs Market
Figure 14.1 Taisho Pharmaceutical Holdings Co Ltd Company Revenue 2016-2020 (US$ Mn, AGR %)
Figure 14.2 Taisho Pharmaceutical Holdings Co Ltd Operating Income 2016-2020(US$ Mn)
Figure 14.3 Taisho Pharmaceutical Holdings Co Ltd EBITDA 2016-2020 (US$Mn)
Figure 14.4 Taisho Pharmaceutical Holdings Co Ltd Net Income/Loss 2015-2019 (US$Mn)
Figure 14.5 Nippon Chemiphar Co., Ltd. Company Revenue 2015-2019(US$Mn, AGR %)
Figure 14.6 Nippon Chemiphar Co., Ltd. Operating Income 2015-2019 (US$Mn)
Figure 14.7 Nippon Chemiphar Co., Ltd. EBITDA 2015-2019 (US$Mn)
Figure 14.8 Nippon Chemiphar Co., Ltd. Net Income/Loss 2015-2019 (US $ Mn)
Figure 14.9 H. Lundbeck A/S Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.10 H. Lundbeck A/S Operating Income 2015-2019 (US$Mn)
Figure 14.11 H. Lundbeck A/S EBITDA 2015-2019 (US$Mn)
Figure 14.12 H. Lundbeck A/S Net Income/Loss 2015-2019 (US$Mn)
Figure 14.13 ASKA Pharmaceutical Co., Ltd. Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.14 ASKA Pharmaceutical Co., Ltd. Operating Income 2015-2019 (US$Mn)
Figure 14.15 ASKA Pharmaceutical Co., Ltd. EBITDA 2015-2019 (US$Mn)
Figure 14.16 ASKA Pharmaceutical Co., Ltd. Net Income/Loss 2015-2019 (US$Mn)
Figure 14.17 Teva Pharmaceuticals Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.18 Teva Pharmaceuticals Operating Income 2015-2019 (US$Mn)
Figure 14.19 Teva Pharmaceuticals EBITDA 2015-2019 (US$Mn)
Figure 14.20 Teva Pharmaceuticals Net Income/Loss 2015-2019 (US$Mn)
Figure 14.21 Novartis AG Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.22 Novartis AG Operating Income 2015-2019 (US$Mn)
Figure 14.23 Novartis AG EBITDA 2015-2019 (US$Mn)
Figure 14.24 Novartis AG Net Income/Loss 2015-2019 (US$Mn)
Figure 14.25 Pfizer Inc. Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.26 Pfizer Inc. Operating Income 2015-2019 (US$Mn)
Figure 14.27 Pfizer Inc. EBITDA 2015-2019 (US$Mn)
Figure 14.28 Pfizer Inc. Net Income/Loss 2015-2019 (US$Mn)
Figure 14.29 Mylan NV Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.30 Mylan NV Operating Income 2015-2019 (US$Mn) Figure 14.31 Mylan NV EBITDA 2015-2019 (US$Mn)
Figure 14.32 Mylan NV Net Income/Loss 2015-2019 (US$Mn)
Figure 14.33 Abbott Laboratories Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.34 Abbott Laboratories Operating Income 2015-2019 (US$Mn)
Figure 14.35 Abbott Laboratories EBITDA 2015-2019 (US$Mn)
Figure 14.36 Abbott Laboratories Net Income/Loss 2015-2019 (US$Mn)
Figure 14.37 Fresenius SE & Co KGaA Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.38 Fresenius SE & Co KGaA Operating Income 2015-2019 (US$Mn)
Figure 14.39 Fresenius SE & Co KGaA EBITDA 2015-2019 (US$Mn)
Figure 14.40 Fresenius SE & Co KGaA Net Income/Loss 2015-2019 (US$Mn)
Figure 14.41 Sun Pharmaceutical Industries Ltd Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.42 Sun Pharmaceutical Industries Ltd Operating Income 2015-2019 (US$Mn)
Figure 14.43 Sun Pharmaceutical Industries Ltd EBITDA 2015-2019 (US$Mn)
Figure 14.44 Sun Pharmaceutical Industries Ltd Net Income/Loss 2015-2019 (US$Mn)
Figure 14.45 Sanofi SA Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 14.46 Sanofi SA Operating Income 2015-2019 (US$Mn)
Figure 14.47 Sanofi SA EBITDA 2015-2019 (US$Mn)
Figure 14.48 Sanofi SA Net Income/Loss 2015-2019 (US$Mn)
Figure 14.49 Roche Holding Company Revenue 2015-2019 (US $Mn, AGR %)
Figure 14.50 Roche Holding Operating Income 2015-2019 (US$Mn)
Figure 14.51 Roche Holding EBITDA 2015-2019 (US$Mn)
Figure 14.52 Roche Holding Net Income/Loss 2015-2019 (US$Mn)
Figure 14.53 Lupin Pharmaceuticals Company Revenue 2015-2019 (US $ Mn, AGR %)
Figure 14.54 Lupin Pharmaceuticals Operating Income 2015-2019 (US$Mn)
Figure 14.55 Lupin Pharmaceuticals EBITDA 2015-2019 (US$Mn)
Figure 14.56 Lupin Pharmaceuticals Net Income/Loss 2015-2019 (US$Mn)
